Redeye provides its initial take on IRRAS’ Q4 report.
Exel’s Q4 EBIT was soft relative to estimates, yet demand doesn’t seem to abate and in our view the ...
Redeye comments on Starbreeze's year-end report. The result was roughly in line with our estimates.
Redeye comments on Stillfront’s Q4-results which was in line with our expectations and company guida...
Atria reported Q4 adjusted EBIT of EUR 10.3m, 19% below Refinitiv consensus.
Redeye has updated its forecasts, which primarily include near-term adjustments due to the absence o...
GPX Medical publicerade idag den 15 februari sin bokslutskommuniké för år 2021.
Redeye comments on Medivir's Q4 report.
Redeye leaves its comment on Respiratorius following the year-end report.
Calliditas lead project in the clinical pipeline besides Nefecon/TARPEYO is Setanaxib targeting prim...
Ascelia Pharma har kommunicerat förändringar i SPARKLE-studien där två nya grupper läggs till i prot...
Freja eID's strong commercial momentum through 2021 laid a promising foundation to fuel its financia...
Exel’s Q4 results extended recent earnings reports trends to a certain degree.
Solteq reports Q4 results on February 17th. We foresee some continued softness due to the current en...
Marimekko’s Q4 result outpaced our estimates and the company grew very strongly.
Probi redovisade ett kvartal präglat av framgångar i Europa och Asien medan utmaningarna i region Am...
Redeye lowers its fair value range on the back of Bambuser's year-end report.
Redeye argues that the lower-than-anticipated sales do not reflect the long-term case of Episurf and...
Redeye updates its estimates following last week's Q4 report, where sales grew double-digit, and pro...
Redeye is cautiously optimistic to yesterday’s licensing agreement between Nexstim and Magnus Medica...
